CMS Plans to Keep Payments to Medicare Advantage Insurers Flat Next Year, Devastating Payer Share Prices

I mentioned yesterday that Merck had dropped its annual drug-price transparency report, warning that Merck’s numbers probably shouldn’t be extrapolated to the broader industry. After all, most companies don’t have

I don’t want to brag, but I was right about the debate, which featured nothing on health policy beyond a couple of throwaway lines … and Trump’s memorable quip about

Yesterday was all about Eliquis. First up were the patient listening sessions I keep prattling on about. And while there was some sense that the parade of speakers didn’t shed